The GRID/CPCA approach in drug discovery

Bibliography

• Brooijmans N, Kuntz ID. Molecular recognition and docking algorithms. Annu Rev Biophys Biomol Struct 2003;32:335-73
   PubMed Web of Science ®Google Scholar
• Davis AM, Teague SJ. Hydrogen bonding, hydrophobic interactions, and failure of the rigid receptor hypothesis. Angew Chem Int Ed 1999;38:736-49
   PubMed Web of Science ®Google Scholar
• Lengauer T, Lemmen C, Rarey M, Zimmermann M. Novel technologies for virtual screening. Drug Discov Today 2004;9:27-34
   PubMed Web of Science ®Google Scholar
• Ghosh S, Nie A, An J, Huang Z. Structure-based virtual screening of chemical libraries for drug discovery. Curr Opin Chem Biol 2006;10:194-202
   PubMed Web of Science ®Google Scholar
• Cheeseright T, Mackey M, Rose S, Vinter A. Molecular field technology applied to virtual screening and finding the bioactive conformation. Exp Opin Drug Discov 2007;2:131-44
   PubMed Web of Science ®Google Scholar
• Leitão A, Andricopulo AA, Montanari CA. 3D quantitative structure-activity relationships: the three-dimensional road to lead design in “current methods in medicinal chemistry and biological physics”. In: Taft CA, Carlos HTP, editors. (Volume 1). Silva Research Signpost 37/661 (2), Fort P.O., Trivandrum-695 023, Kerala, India; 2007. p. 61-90. ISBN: 81-308-0141-8
   Google Scholar
• Cross S, Cruciani G. Molecular fields in drug discovery: getting old or reaching maturity? Drug Discov Today 2009: published online 14 January 2009, doi: 10.1016/j.drudis.2008.12.006
   PubMed Web of Science ®Google Scholar
• Crivori P, Cruciani G, Carrupt PA, Testa B. Predicting blood-brain barrier permeation from three-dimensional molecular structure. J Med Chem 2000;43:2204-16
   PubMed Web of Science ®Google Scholar
• Cramer III RD, Patterson DE, Bunce JD. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 1988;110:5959-67
   PubMed Web of Science ®Google Scholar
• Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 1985;28:849-57
   PubMed Web of Science ®Google Scholar
• von Itzstein M, Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993;363:418-23
   PubMed Web of Science ®Google Scholar
• Schmitt S, Kuhn D, Klebe G. A New method to detect related function among proteins independent of sequence and fold homology. J Mol Bio 2002;323:387-406
   PubMed Web of Science ®Google Scholar
• Daniel K, Nils W, Eyke H, Gerhard G. Functional classification of protein kinase binding sites using Cavbase. ChemMedChem 2007;2:1432-47
   PubMed Web of Science ®Google Scholar
• Weber A, Casini A, Heine A, Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem 2003;47:550-57
   Web of Science ®Google Scholar
• Kuhn D, Weskamp N, Schmitt S, From the similarity analysis of protein cavities to the functional classification of protein families using cavbase. J Mol Biol 2006;359:1023-44
   PubMed Web of Science ®Google Scholar
• Cruciani G, Goodford PJ. A search for specificity in DNA-drug interactions. J Mol Graph 1994;12:116-29
   PubMedGoogle Scholar
• Pastor M, Cruciani G. A novel strategy for improving ligand selectivity in receptor-based drug design. J Med Chem 1995;38:4637-47
   PubMed Web of Science ®Google Scholar
• Ridderström M, Zamora I, Fjellström O, Andersson TB. Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA. J Med Chem 2001;44:4072-81
   PubMed Web of Science ®Google Scholar
• Cruciani G. Molecular interaction fields: application in drug discovery and ADME prediction. Wiley-VCH, Zurich, 2006
   Google Scholar
• Leach AR, Gillet VJ. An introduction to chemoinformatics. Springer, Dordrecht, 2007
   Google Scholar
• Kastenholz MA, Pastor M, Cruciani G, GRID/CPCA: a new computational tool to design selective ligands. J Med Chem 2000;43:3033-44
   PubMed Web of Science ®Google Scholar
• Montanari MLC, Andricopulo AD, Montanari CA. Calorimetry and structure-activity relationships for a series of antimicrobial hydrazides. Thermochimica Acta 2004;417:283-94
   Web of Science ®Google Scholar
• Davis AM, St-Gallay SA, Kleywegt GJ. Limitations and lessons in the use of X-ray structural information in drug design. Drug Discov Today 2008;13:831-41
   PubMed Web of Science ®Google Scholar
• Terp GE, Cruciani G, Christensen IT, Jorgensen FS. Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach. J Med Chem 2002;45:2675-84
   PubMed Web of Science ®Google Scholar
• Myshkin E, Wang B. Chemometrical classification of ephrin ligands and Eph kinases using GRID/CPCA approach. J Chem Inf Comput Sci 2003;43:1004-10
   PubMedGoogle Scholar
• Matter H, Kumar HSA, Fedorov R, Structural analysis of isoform-specific inhibitors targeting the tetrahydrobiopterin binding site of human nitric oxide synthases. J Med Chem 2005;48:4783-92
   PubMed Web of Science ®Google Scholar
• Pirard B. Peroxisome proliferator-activated receptors target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis. J Comput Aided Mol Design 2003;17:785-96
   PubMed Web of Science ®Google Scholar
• Vulpetti A, Crivori P, Cameron A, Structure-based approaches to improve selectivity: CDK2-GSK3 binding site analysis. J Chem Inf Model 2005;45:1282-90
   PubMed Web of Science ®Google Scholar
• Ji H, Li H, Flinspach M, Computer modeling of selective regions in the active site of nitric oxide synthases: implication for the design of isoform-selective inhibitors. J Med Chem 2003;46:5700-11
   PubMed Web of Science ®Google Scholar
• Cruciani G, Carosati E, De Boeck B, MetaSite: understanding metabolism in human cytochromes from the perspective of the Chemist. J Med Chem 2005;48:6970-79
   PubMed Web of Science ®Google Scholar
• Matter H, Schwab W. Affinity and selectivity of matrix metalloproteinase inhibitors: a chemometrical study fromthe perspective of ligands and proteins. J Med Chem 1999;42:4506-23
   PubMed Web of Science ®Google Scholar
• Filipponi E, Cecchetti V, Tabarrini O, Chemometric rationalization of the structural andphysicochemical basis for selective cyclooxygenase-2 inhibition: toward more specific ligands. J Comput AidedMol Des 2000;14:277-91
   PubMed Web of Science ®Google Scholar
• Braiuca P, Ebert C, Fischer L, A homology model of penicillin acylase from Alcaligenes faecalis and in silico evaluation of its selectivity. ChemBioChem 2003;4:615-22
   PubMed Web of Science ®Google Scholar
• Braiuca P, Cruciani G, Ebert C, An innovative application of the “flexible” GRID/PCA computational method: study of differences in selectivity between PGAs from Escherichia coli and a Providentia rettgeri mutant. Biotechnol Prog 2004;20:1025-31
   PubMed Web of Science ®Google Scholar
• Nicolotti O, Miscioscia TF, Carotti A, An integrated approach to ligand- and structure-based drug design: development and application to a series of serine protease inhibitors. J Chem Inf Model 2008;48:1211-26
   PubMed Web of Science ®Google Scholar
• Gohlke H, Klebe G. DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein. J Med Chem 2002;45:4153-70
   PubMed Web of Science ®Google Scholar
• Afzelius L, Raubacher F, Karlén A, Structural analysis of CYP2C9 and CYP2C5 and an evaluation of commonly used molecular modeling techniques, Drug Metab Dispos 2004;32:1218-29
   PubMed Web of Science ®Google Scholar
• Naumann T, Matter H. Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes. J Med Chem 2002;45:2366-78
   PubMed Web of Science ®Google Scholar
• Pirard B, Matter H. Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis. J Med Chem 2006;49:51-69
   PubMed Web of Science ®Google Scholar
• Matter H, Kotsonis P. Biology and chemistry of the inhibition of nitric oxide synthases by pteridine-derivatives as therapeutic agents. Med Res Rev 2004;24:662-84
   PubMed Web of Science ®Google Scholar
• Pirard B. Computational methods for the identification and optimisation of high quality leads. Comb Chem High Throughput Screen 2004;7:271-80
   PubMed Web of Science ®Google Scholar
• Kurz M, Brachvogel V, Matter H, Insights into the bile acid transportation system: the human ileal lipid-binding protein-cholyltaurine complex and its comparison with homologous structures. Proteins Struct Funct Genet 2003;50:312-28
   PubMed Web of Science ®Google Scholar
• de Menezes IRA, Leitão A, Montanari CA. Estrogen receptor: structural differences and potential implications on selectivity examined by the GRID/CPCA approach. Lett Drug Design Discov 2008;5:182-92
   Web of Science ®Google Scholar
• Menezes IRA, Leitão A, Montanari CA. Three-dimensional models of non-steroidal ligands: a comparative molecular field analysis. Steroids 2006;71:417-28
   PubMed Web of Science ®Google Scholar
• Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: Structure, function and inhibition. Biochem J 2001;357:593-615
   PubMed Web of Science ®Google Scholar
• Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 2005;4:825-33
   PubMed Web of Science ®Google Scholar
• Lill MA, Dobler M, Vedani A. Prediction of small-molecule binding to cytochrome P450 3A4: flexible docking combined with multidimensional QSAR. ChemMedChem 2006;1:73-81
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhu M, Humphreys WG, Iyer R. Role of drug metabolism in drug development. John Wiley & Sons: Hoboken, NJ, 2008
   Google Scholar
• Breu B, Silber K, andGohlke H. Consensus adaptation of fields for molecular comparison (AFMoC) models incorporate ligand and receptor conformational variability into tailor-made scoring functions. J Chem Inf Model 2007;47:2383-400
   PubMed Web of Science ®Google Scholar
• Skiles JW, Gonnella NC, Jeng AY. The design, structure, and therapeutic application of matrix metalloprotease inhibitors. Curr Med Chem 2001;8:425-74
   PubMed Web of Science ®Google Scholar
• Robinson RP, Laird ER, Blake JF, Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold. J Med Chem 2000;43:2293-96
   PubMed Web of Science ®Google Scholar
• Hanessian S, MacKay DB, Moitessier N. Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S1 pocket using conformationally constrained inhibitors. J Med Chem 2001;44:3074-82
   PubMed Web of Science ®Google Scholar
• Wu J, Rush TS III, Hotchandani R, Identification of potent and selective MMP-13 inhibitors. Bioorg Med Chem Lett 2005;15:4105-9
   PubMed Web of Science ®Google Scholar
• Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Ver Drug Discov 2004;3:1001-10
   PubMed Web of Science ®Google Scholar
• Pastor M, Cruciani G, Mclay I, GRID-independent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. J Med Chem 2000;43:3233-43
   PubMed Web of Science ®Google Scholar
• Gutiérrez-de-Terán H, Centeno NB, Pastor M, Sanz F. Novel approaches for modeling of the A1 adenosine receptor and its agonist binding site. Proteins Struct Funct Bioinformatics 2004;54:705-15
   PubMed Web of Science ®Google Scholar
• Lomize AL, Reibarkh MY, Pogozheva ID. Interatomic potentials and solvation parameters from protein engineering data for buried residues. Protein Sci 2002;11:1984-2000
   PubMed Web of Science ®Google Scholar
• Mittal RR, Harris L, McKinnon RA, Sorich MJ. Partial charge calculation method affects CoMFA QSAR prediction accuracy. J Chem Information Model 2009;49:704-9
   PubMed Web of Science ®Google Scholar
• Liljefors T. Progress in force-field calculations of molecular interaction fields and intermolecular interactions. Perspectives in Drug Discovery and Design 1998;9-11:3-17
   Google Scholar
• Olsson TS, Williams MA, Pitt WR, Ladbury JE. The thermodynamics of protein-ligand interaction and solvation: insights for ligand design. J Mol Biol 2008;384:1002-17
   PubMed Web of Science ®Google Scholar
• Koshland DE. Application of a theory of enzyme specificity to protein synthesis. Proc Natl Acad Sci 1958;44:98-104
   PubMed Web of Science ®Google Scholar
• Davis AM, Teague SJ, Kleywegt GJ. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. Angew Chem Int Ed 2003;42:2718-36
   PubMed Web of Science ®Google Scholar
• Ababou A, Ladbury JE. Survey of the year 2005: literature on applications of isothermal titration calorimetry J Mol Recognit 2007;20:4-14
   PubMed Web of Science ®Google Scholar
• Klebe G, Abraham U, Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 1994;37:4130-146
   PubMed Web of Science ®Google Scholar
• Kellogg GE, Semus SF, Abraham DJ. HINT: a new method of empirical hydrophobic field calculation for CoMFA. J Comput Aid Mol Des 1991;5:545-52
   PubMed Web of Science ®Google Scholar
• Doweyko AM, The hypothetical active site lattice– in vitro and in vivo explorations using a three-dimensional QSAR technique. J Math Chem 1991;7:273-85
   Web of Science ®Google Scholar
• Jain AN, Koile K, Chapman D. Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark. J Med Chem 1994;37:2315-27
   PubMed Web of Science ®Google Scholar
• Baroni M, Cruciani G, Sciabola S, A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for ligands and proteins (FLAP): theory and application. J Chem Inf Model 2007;47:279-94
   PubMed Web of Science ®Google Scholar
• Goodford P. Multivariate characterization of molecules for QSAR analysis. J Chemom 1996;10:107-17
   Web of Science ®Google Scholar
• Cruciani G, Pastor M, Guba W. VolSurf, a new tool for the pharmacokinetic optimization of lead compounds. Eur J Pharm Sci 2000;11:S29-39
   PubMed Web of Science ®Google Scholar
• Verdonk ML, Cole JC, Taylor R. SuperStar: a knowledge-based approach for identifying interaction sites in proteins. J Mol Biol 1999;289:1093-108
   PubMed Web of Science ®Google Scholar
• Verdonk ML, Cole JC, Watson P, SuperStar: improved knowledge-based interaction fields for protein binding sites. J Mol Biol 2001;307:841-59
   PubMed Web of Science ®Google Scholar
• Pirard B. Structure-based chemogenomics: analysis of protein family landscapes in “Chemogenomics: Methods and Applications”. Series: Methods in Molecular Biology, 2009;575:281-96
   Google Scholar